• University of Leeds Featured PhD Programmes
  • University of Glasgow Featured PhD Programmes
  • Carlos III Health Institute Featured PhD Programmes
  • University of Leeds Featured PhD Programmes
  • University of Cambridge Featured PhD Programmes
  • London School of Economics and Political Science Featured PhD Programmes
  • University of Mannheim Featured PhD Programmes
  • University of Bristol Featured PhD Programmes
Wellcome Trust Featured PhD Programmes
University of Glasgow Featured PhD Programmes
University of Kent Featured PhD Programmes
King Abdullah University of Science and Technology (KAUST) Featured PhD Programmes
University of Manchester Featured PhD Programmes

Pharmacokinetics and pharmacodynamics of cordycepin, a potential lead drug in osteoarthritis

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr Gershkovich
  • Application Deadline
    Applications accepted all year round
  • Self-Funded PhD Students Only
    Self-Funded PhD Students Only

Project Description

Osteoarthritis is a common cause of pain and loss of flexibility in joints. It is characterised by a loss of cartilage, changes in the bone structure and synovitis in the affected joint. Treatment options are currently largely limited to exercise, non-steroid anti-inflammatory drugs, corticosteroids, opioid pain killers and surgery.
Cordycepin (3’ deoxyadenosine) is isolated from a fungus that is used as a health food and traditional medicine throughout the Far East. We have previously shown that cordycepin has anti-inflammatory properties through its effects on polyadenylation, the last step of mRNA synthesis. The specificity of the effect of polyadenylation inhibition on inflammatory mRNAs opens up the possibility that cordycepin could be a lead drug for the treatment of inflammatory disease.
The purpose of this project is to assess the biopharmaceutical properties of cordycepin, including its pharmacokinetics and biodistribution in order to evaluate the potential of cordycepin for the treatment of osteoarthritis.
Understanding where and how cordycepin is absorbed and how it distributes around the body is very important for the future development of better analogues with higher efficacy and low toxicity. This project will also help with the design of improved formulation and administration of unmodified cordycepin, e.g. it will indicate if intra-articular injection or a combination with a low dose of other compounds could improve the response.

Funding Notes

Applications are invited from self-funded students.
The project will be co-supervised by Dr Cornelia De Moor and Dr Pavel Gershkovich in the University of Nottingham, UK.
For informal inquiries please contact Dr Pavel Gershkovich ([email protected]) or Dr Cornelia De Moor ([email protected]).

How good is research at University of Nottingham in Allied Health Professions, Dentistry, Nursing and Pharmacy?
Pharmacy

FTE Category A staff submitted: 44.10

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities
Share this page:

Cookie Policy    X